@prefix activity: .
@prefix address: .
@prefix agency: .
@prefix assay: .
@prefix assayCategory: .
@prefix assayTargetLink: .
@prefix biopax3: .
@prefix calbc: .
@prefix calbc-group: .
@prefix carrierLink: .
@prefix certainAgreement: .
@prefix chebi: .
@prefix chembl: .
@prefix chemicalCompound: .
@prefix chemicalCompoundRecord: .
@prefix clan: .
@prefix clinicalResult: .
@prefix clinicalStudy: .
@prefix clinicaltrials: .
@prefix company: .
@prefix confidenceScore: .
@prefix contact: .
@prefix country: .
@prefix cpath: .
@prefix curationLookup: .
@prefix dailymed: .
@prefix dailymed-drugs: .
@prefix dailymed-ingredient: .
@prefix dailymed-instance: .
@prefix databaseReference: .
@prefix dc: .
@prefix dc-term: .
@prefix diseaseontology: .
@prefix diseasome: .
@prefix diseasome-diseases: .
@prefix diseasome-gene: .
@prefix diseasome-instance: .
@prefix documentType: .
@prefix dosageForm: .
@prefix drug: .
@prefix drugbank: .
@prefix drugbank-proteinSequence: .
@prefix drugCategory: .
@prefix drugInteraction: .
@prefix drugTarget: .
@prefix eligibility: .
@prefix entrez-gene: .
@prefix entrez-goterm: .
@prefix entrezgene: .
@prefix enzymeLink: .
@prefix externalIdentifier: .
@prefix externalLink: .
@prefix factforge: .
@prefix family: .
@prefix foaf: .
@prefix formulation: .
@prefix freebase: .
@prefix gene-rif: .
@prefix geneontology: .
@prefix geneSequence: .
@prefix hapmap: .
@prefix indication: .
@prefix intervention: .
@prefix investigator: .
@prefix label: .
@prefix lhgdn: .
@prefix lifeskim: .
@prefix linkedct: .
@prefix linkedct-condition: .
@prefix linkedct-intervention: .
@prefix literatureCitation: .
@prefix lld: .
@prefix location: .
@prefix measurement: .
@prefix meddraSideEffect: .
@prefix mixture: .
@prefix molecularSpecies: .
@prefix molecule: .
@prefix moleculeType: .
@prefix ontotext: .
@prefix organismSpecies: .
@prefix outcomeAnalysis: .
@prefix outcomeMeasure: .
@prefix overallOfficial: .
@prefix owl: .
@prefix owlim: .
@prefix packager: .
@prefix participantFlow: .
@prefix patent: .
@prefix pfam: .
@prefix phenotype: .
@prefix pointOfContact: .
@prefix price: .
@prefix primaryOutcome: .
@prefix product: .
@prefix property: .
@prefix proteinSequence: .
@prefix pubmed: .
@prefix pubmed-article: .
@prefix pubmed-author: .
@prefix pubmed-mesh: .
@prefix pubmed-meshheading: .
@prefix pubmed-qualifier: .
@prefix rdf: .
@prefix rdfs: .
@prefix relationshipType: .
@prefix relontology: .
@prefix reportingGroup: .
@prefix researchStem: .
@prefix responsibleParty: .
@prefix result: .
@prefix resultsBaseline: .
@prefix resultsMeasure: .
@prefix resultsOutcome: .
@prefix secondaryOutcome: .
@prefix sideEffect: .
@prefix sideEffectFrequency: .
@prefix sider: .
@prefix sider-drug: .
@prefix skos: .
@prefix skos-xl: .
@prefix snp: .
@prefix structureType: .
@prefix studyMilestone: .
@prefix studyParticipants: .
@prefix studyPeriod: .
@prefix substructure: .
@prefix symptom: .
@prefix synonym: .
@prefix targetLink: .
@prefix targetType: .
@prefix taxonomy: .
@prefix taxonomyClass: .
@prefix taxonomyKingdom: .
@prefix transporterLink: .
@prefix umls: .
@prefix umls-concept: .
@prefix umls-label: .
@prefix umls-semnetwork: .
@prefix uniprot: .
@prefix uniprot-protein: .
@prefix uniprot-unstable: .
@prefix xsd: .
pubmed-article:15775976 a pubmed:Citation ;
lifeskim:mentions umls-concept:C0027651 , umls-concept:C1705280 , umls-concept:C2827404 , umls-concept:C0022660 , umls-concept:C0079904 , umls-concept:C0525037 , umls-concept:C0079419 , umls-concept:C1332120 , umls-concept:C1332753 , umls-concept:C0851285 , umls-concept:C1879547 , umls-concept:C2003905 ;
pubmed:issue "6" ;
pubmed:dateCreated "2005-4-25" ;
pubmed:abstractText "The ARF tumour suppressor is a central component of the cellular defence against oncogene activation. In addition to activating p53 through binding Mdm2, ARF possesses other functions, including an ability to repress the transcriptional activity of the antiapoptotic RelA(p65) NF-kappaB subunit. Here we demonstrate that ARF induces the ATR- and Chk1-dependent phosphorylation of the RelA transactivation domain at threonine 505, a site required for ARF-dependent repression of RelA transcriptional activity. Consistent with this effect, ATR and Chk1 are required for ARF-induced sensitivity to tumour necrosis factor alpha-induced cell death. Significantly, ATR activity is also required for ARF-induced p53 activity and inhibition of proliferation. ARF achieves these effects by activating ATR and Chk1. Furthermore, ATR and its scaffold protein BRCA1, but not Chk1, relocalise to specific nucleolar sites. These results reveal novel functions for ARF, ATR and Chk1 together with a new pathway regulating RelA NF-kappaB function. Moreover, this pathway provides a mechanism through which ARF can remodel the cellular response to an oncogenic challenge and execute its function as a tumour suppressor." ;
pubmed:commentsCorrections , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ;
pubmed:language "eng" ;
pubmed:journal ;
pubmed:citationSubset "IM" ;
pubmed:chemical , , , , , , , , , , , , ;
pubmed:status "MEDLINE" ;
pubmed:month "Mar" ;
pubmed:issn "0261-4189" ;
pubmed:author , , pubmed-author:RochaSoniaS , , pubmed-author:SchummKatieK ;
pubmed:issnType "Print" ;
pubmed:day "23" ;
pubmed:volume "24" ;
pubmed:owner "NLM" ;
pubmed:authorsComplete "Y" ;
pubmed:pagination "1157-69" ;
pubmed:dateRevised "2011-11-2" ;
pubmed:meshHeading pubmed-meshheading:15775976-Humans , pubmed-meshheading:15775976-Serine , pubmed-meshheading:15775976-Threonine , pubmed-meshheading:15775976-Phosphorylation , , , , , , , , , , , , , , ;
pubmed:year "2005" ;
pubmed:articleTitle "Regulation of NF-kappaB and p53 through activation of ATR and Chk1 by the ARF tumour suppressor." ;
pubmed:affiliation "School of Life Sciences, Division of Gene Regulation and Expression, University of Dundee, Dundee, Scotland, UK." ;
pubmed:publicationType "Journal Article" , "Research Support, Non-U.S. Gov't" .